Teva won't say whether R&D cuts include layoffs; Cipla inks deal for Iranian plant;

teva logo

@FiercePharma: Top-read special report Monday: Top 10 pharma companies by employees - 2014. Feature | Follow @FiercePharma

@CarlyHFierce: One more time: Our latest special report, Top women in biotech 2014. Good stuff right here. Feature | Follow @CarlyHFierce

> Teva Pharmaceutical Industries ($TEVA) won't yet say how many jobs might be affected by its plans to ratchet back R&D in women's health and oncology. Report

Free Amazon Webinar

Performing end to end real-world evidence generation in the cloud with traceability and transparency- a Sanofi journey

In this webinar you will hear about Sanofi’s journey and experience in building an industrialized big data & analytics platform in the cloud that handles billions of rows of RWD data with complete data traceability, security, and supports both traditional and advanced analytics for day to day evidence generation (RWE).

> Regeneron's ($REGN) ophthalmic injection Eylea won FDA approval for yet another indication, this time in patients with macular edema folowing retinal vein occlusion. Release

> Indian generics maker Cipla inked a partnership to set up a manufacturing plant in Iran, as part of a strategy to boost its presence there and expand far beyond its home market. Report

Medical Device News

@FierceMedDev: ICYMI yesterday: Optos, NHS and academia in $16M partnership for eye disease diagnostic. Article | Follow @FierceMedDev

@VarunSaxena2: Larry Wood of Edwards "Everybody's embarrassed that we were the 43rd country to get TAVR." Around same time as Brazil, Albania. | Follow @VarunSaxena2

@EmilyWFierce: Scalability and cost could be potential hurdles to bringing experimental CAR T-cell therapies to patients. More from the WSJ | Follow @EmilyWFierce

@MichaelGFierce: From our Women in Biotech Feature: Adelene Perkins of $INFI says, "Our endeavor is by definition a team sport." More | Follow @MichaelGFierce

> NanoString teams up with Brigham and Women's Hospital for cancer Dx development. More

> Unilife inks 15-year deal with Sanofi for wearable injectors. Story

> GE promotes biz dev exec to head healthcare. Report

Biotech News

@FierceBiotech: Every year Women in Biotech gets a ton of readers, and this issue is no exception. Trending nicely. Report | Follow @FierceBiotech

@JohnCFierce: In a surprise move, Bristol-Myers drops U.S. approval plans for hep C drug. News | Follow @JohnCFierce

@DamianFierce: CRO INC Research files for a $150M IPO, following in the footsteps of $Q, $CTLT and PRA. SEC filing | Follow @DamianFierce

@EmilyMFierce: Programmed antibiotics kill drug-resistant bacteria. More from FierceBiotech Research | Follow @EmilyMFierce

> Another CRO heads to Wall Street as INC swings for $150M. Report

> Bellicum puts up $50M for Ariad's R&D tech. Item

> Positive PhIII PONV study brings little Acacia to a crossroads. Story

> With help from Eli Lilly, TVM pushes its build-to-buy fund to $201M. News

Biotech Research News

> NIH doles out first $46M round of BRAIN Initiative grants. Report

> Gene therapy technique could treat rare lung disease. More

> Programmed antibiotics kill drug-resistant bacteria. Story

> Ebola genome browser launched to aid drug discovery. Article

> $19M in FDA grants will support rare disease research. Item

Pharma Manufacturing News

> Cipla works with partner to build a manufacturing plant in Iran. More

> West Pharmaceutical confirms it's building $126M facility in Ireland. Story

> Patheon to add almost 500 jobs over 5 years as it expands in NC. Article

> India's IPCA buys plant as it deals with FDA issues. Item

> New FDA concerns arise for Hospira plant in Australia. Report

And Finally... Sucampo Pharmaceuticals ($SCMP) said its CFO, Cary Claiborne, would be leaving the company as of Nov. 7; a successor hasn't yet been named. Release

Suggested Articles

Merck’s Keytruda went up against chemo in a head-to-head colorectal cancer battle—and won.

While the FDA gave an emergency green light to chloroquine's use against coronavirus, European regulators are restricting the drug to clinical trials.

Biocon has finally satisfied the FDA that its insulin production plant in Malaysia is ready for prime time.